BACKGROUND
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. However, the role of small ubiquitin-like modifier 2 (SUMO2), a core member of the small ubiquitin-like modifier (SUMO) family, regarding its expression patterns and metabolism-related functions in HCC remains inade...
Yu-Long Deng, Bei-Bei Huang, Yu-Xing Tang et al.· Frontiers in Bioscience· 0 citations
This study identified GPATCH4, CCT3, C19orf53, UACA, PPM1M, and LIN37 as key genes mediating TKI resistance in HCC, and identified Ferroptosis, epithelial‐mesenchymal transition and hypoxia were new research directions, which were closely related to the pathways investigated in this study.
Siyi Chen, Li-Hua Yang, Zi-Qian Liang et al.· Cancer Medicine· 0 citations
NOL12 may be regulated by the putative miR‐1246‐5p/H3K27ac enhancer axis and promotes HCC progression through the spliceosome pathway, supporting its potential as a novel therapeutic target for HCC.
Li Xiao, Yu-Long Deng, Li-Na Liang et al.· IET Systems Biology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.